Lv1
28 积分 2021-10-04 加入
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
1个月前
已完结
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
1个月前
已完结
IgA Nephropathy in Adults
2个月前
已完结
A Comprehensive Review of Marketed KRAS Inhibitors and Degraders: Challenges and Opportunities
2个月前
已完结
Role of Transforming Growth Factor-beta Signaling in Cancer
2个月前
已完结
Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells
2个月前
已完结
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
2个月前
已完结
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
3个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
3个月前
已完结
VEGF signaling: Role in angiogenesis and beyond
6个月前
已完结
皖公网安备34019202002308
